Leveraging real-world evidence to understand the therapeutic potential of FGFR alterations in Urothelial Carcinoma

 

ESFURN stands for European Study of FGFR (Fibroblast Growth Factor Receptors) in URothelial Neoplams and was launched by Janssen to address the current challenges in understanding the prognostic and predictive values of FGFR alterations in urothelial carcinoma. This initiative intends to develop a federated network across European partners sites, standardized to a common data model, allowing real-word data analysis and evidence sharing for collaborative research.

How does it work?

The federated model enables partners to keep full control of their data and the analysis. The original source data are transformed at the partners site to the OMOP CDM (Observational Medical Outcomes Partnership Common Data Model), which also stays local. The analysis is carried out locally at the partners site and the anonymized aggregated results are stored and shared on a secure platform which ensures complete patient privacy. This secured environment is only accessible to ESFURN partners.

The federated data network structure also allows to add new sites to enrich access to data and increase the power of the results. It has the potential to address additional research questions by leveraging multiple data sources and fostering future collaboration.

 

Taking a step closer to precision medicine